Research Programs

The Charles Lazarus Children’s Abilities Center participates in a variety of state-of-the-art research projects to improve performance for patients of all ages.

The Evaluation of an Electroencephalography-based Concussion System

  • Objective: Conduct a clinical trial of a concussion system based on electroencephalography to determine how well the device detects concussion. We will compare the outputs from the device with a physician's diagnosis. Each assessment with the device will take approximately 15 minutes. Participants will complete testing with the device at their initial medical consultation post-injury and at up to five follow-up visits post-injury.
  • Criteria: Group A: People with sustained suspected concussion; Group B: Healthy controls
  • Duration: Group A: 28 days; Group B: 30 minutes, one session
  • Principal Investigator: David Putrino, PhD
  • Dates: October 2018 – open ended
  • Contact:

Usability and effectiveness of an augmented respiratory rehabilitation game

  • Objective: Develop an augmented reality game that promotes rehabilitation (airway clearance and exercise) in children with respiratory diseases such as cystic fibrosis and bronchiectasis. We will examine the usability of the game and its effectiveness in improving adherence to daily treatments such as airway clearance and exercise.
  • Criteria: Children with cystic fibrosis (CF) and non-CF bronchiectasis
  • Duration: One month usability study; six-month adherence study
  • Principal Investigator: Jamie Wood, PhD
  • Dates: TBA/commencing Q3 2021
  • Contact:

Development of a low-cost airway clearance device for respiratory diseases

  • Objective: Design a low-cost airway clearance device and compare the pressure generated at different expiratory flow rates to that of existing devices. We will then assess the device for satisfaction among children and adults with respiratory diseases. The goal is to provide it to patients in low-income areas and countries.
  • Criteria: Children and adults with any respiratory diseases.
  • Duration: One-month initial lab testing, three-month Phase I clinical study, six-month Phase II clinical study.
  • Principal Investigator: Jamie Wood, PhD
  • Dates: Commencing Q1 2021
  • Contact:

Mechanism of Action for Effects from Automated Mechanical Peripheral Stimulation (AMPS) delivered by the Gondola device

  • Objective: Determine whether multiple sessions of AMPS improves voluntary motor drive or cortico-spinal excitability in chronic stroke and cerebral palsy.
  • Inclusion criteria: age 18 to 80; chronic stroke lesion >6 months after a cerebrovascular accident; diagnosis of cerebral palsy; presence of some degree of motor function in the ankle plantar flexor; able to ambulate 10 meters without physical assistance
  • Exclusion criteria: medically unstable condition; presence of other concurrent neurological illness; cognitive impairment; diabetic vasculopathy; gouty joint condition; serious heart disease; presence of any potential transcranial magnetic stimulation/Gondola risk factor: ulcer, skin lesion, amputation or recent bone fracture at the site of stimulation; presence of an electrically, magnetically or mechanically activated implant, an intracerebral vascular clip, or any other electrically sensitive support system; family history of medication-resistant epilepsy; and past history of seizures or unexplained spells of loss of consciousness.
  • Duration: 4 weeks (12 sessions total)
  • Principal Investigator: David Putrino, PT, PhD
  • Dates: TBD, likely to start fall 2021
  • Contact:

Feasibility and user accessibility of a gamified sensorimotor assessment in children with cerebral palsy

  • Objective: To determine usability and enjoyability of a gamified sensorimotor gaming platform designed to assess cognitive, motor, and perceptual skills via artificial intelligence-driven battery of tasks (Aim Lab) in school aged children with cerebral palsy. 
  • Criteria: School-aged (8-17) children with cerebral palsy who experience upper extremity movement impairments
  • Duration: 2.5 hours with the option for participation in a longer duration trial
  • Principal Investigator: David Putrino, PhD
  • Dates: TBA/Q3 2021
  • Contact: